Cargando…

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East

BACKGROUND: Evidence on the use of fingolimod in real-world clinical practice and data on patient-reported health-related quality of life (HRQoL) in countries such as the Middle East are sparse. The Prospective Evaluation of Treatment with Fingolimod for Multiple Sclerosis (PERFORMS) study assessed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Achiron, Anat, Aref, Hany, Inshasi, Jihad, Harb, Mohamad, Alroughani, Raed, Bijarnia, Mahendra, Cooke, Kathryn, Yuksel, Ozgur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547540/ https://www.ncbi.nlm.nih.gov/pubmed/28784108 http://dx.doi.org/10.1186/s12883-017-0913-3

Ejemplares similares

Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East
por: Alroughani, Raed, et al.
Publicado: (2022)

Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East
por: Alroughani, Raed, et al.
Publicado: (2022)

Neuromyelitis optica spectrum disorders in the Arabian Gulf: challenges and growing experience
por: Alroughani, Raed, et al.
Publicado: (2020)

Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring
por: Alroughani, Raed A, et al.
Publicado: (2014)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

MENACTRIMS practice guideline for COVID-19 vaccination in patients with multiple sclerosis
por: Yamout, Bassem I, et al.
Publicado: (2021)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Disease-Modifying Drugs and Family Planning in People with Multiple Sclerosis: A Consensus Narrative Review from the Gulf Region
por: Alroughani, Raed, et al.
Publicado: (2020)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study
por: Gold, Ralf, et al.
Publicado: (2013)

Expert Consensus and Narrative Review on the Management of Multiple Sclerosis in the Arabian Gulf in the COVID-19 Era: Focus on Disease-Modifying Therapies and Vaccination Against COVID-19
por: Inshasi, Jihad, et al.
Publicado: (2021)

Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod
por: Achiron, Anat, et al.
Publicado: (2022)

An Overview of High-Efficacy Drugs for Multiple Sclerosis: Gulf Region Expert Opinion
por: Alroughani, Raed, et al.
Publicado: (2019)

COVID19 in Multiple Sclerosis Patients in Dubai: Observational Study
por: Thakre, Mona, et al.
Publicado: (2022)

Future of Management of Multiple Sclerosis in the Middle East: A Consensus View from Specialists in Ten Countries
por: Aljumah, Mohammed, et al.
Publicado: (2013)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

The use of alemtuzumab in patients with relapsing-remitting multiple sclerosis: the Gulf perspective
por: Alroughani, Raed, et al.
Publicado: (2020)

Improving communication with multiple sclerosis patients
por: Alroughani, Raed A.
Publicado: (2015)

A cortical stroke secondary to an isolated left ventricular noncompaction in a 29-year-old female
por: Younan, Hany, et al.
Publicado: (2016)

Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study
por: Inshasi, Jihad, et al.
Publicado: (2023)

Pediatric multiple sclerosis: a review
por: Alroughani, Raed, et al.
Publicado: (2018)

Real-world effectiveness and safety profile of teriflunomide in the management of multiple sclerosis in the Gulf Cooperation Council countries: An expert consensus narrative review
por: Alroughani, Raed, et al.
Publicado: (2022)

Real-world experience on the use of COVID-19 vaccination in patients with multiple sclerosis treated with Cladribine tablets in the Gulf region
por: Inshasi, Jihad, et al.
Publicado: (2022)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Urinary diseases and ethnobotany among pastoral nomads in the Middle East
por: Abu-Rabia, Aref
Publicado: (2005)

Injury to white matter tracts in relapsing–remitting multiple sclerosis: A possible therapeutic window within the first 5 years from onset using diffusion-tensor imaging tract-based spatial statistics
por: Asaf, Achiron, et al.
Publicado: (2015)

Can Blood Gene Expression Predict Which Patients with Multiple Sclerosis Will Respond to Interferon?
por: Kaminski, Naftali, et al.
Publicado: (2005)

Pregnancy and the Use of Disease-Modifying Therapies in Patients with Multiple Sclerosis: Benefits versus Risks
por: Alroughani, Raed, et al.
Publicado: (2016)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

Optimizing multiple sclerosis diagnosis: gene expression and genomic association
por: Gurevich, Michael, et al.
Publicado: (2015)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
por: Achiron, Anat, et al.
Publicado: (2009)

Effectiveness and Safety of Dimethyl Fumarate Treatment in Relapsing Multiple Sclerosis Patients: Real-World Evidence
por: Alroughani, Raed, et al.
Publicado: (2017)

Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group
por: Fazekas, Franz
Publicado: (2012)

A matched case-control study of risk factors associated with multiple sclerosis in Kuwait
por: El-Muzaini, Hadeel, et al.
Publicado: (2020)

Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study
por: Kalron, Alon, et al.
Publicado: (2016)

Optical Coherence Tomography Is Associated With Cognitive Impairment in Multiple Sclerosis
por: Dreyer-Alster, Sapir, et al.
Publicado: (2022)

Correction to: A matched case-control study of risk factors associated with multiple sclerosis in Kuwait
por: El-Muzaini, Hadeel, et al.
Publicado: (2020)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Myeloid cells as target of fingolimod action in multiple sclerosis
por: Di Dario, Marco, et al.
Publicado: (2015)

An observational study of alemtuzumab following fingolimod for multiple sclerosis
por: Willis, Mark, et al.
Publicado: (2017)

Risk factors for fingolimod-induced lymphopenia in multiple sclerosis
por: Ohtani, Ryohei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_q9g45hmngrul5d5ek1emhdmh3j